Your browser doesn't support javascript.
loading
The immunosuppressive effects of low molecular weight chitosan on thymopentin-activated mice bearing H22 solid tumors.
Ji, Hai-Yu; Liu, Chao; Dai, Ke-Yao; Yu, Juan; Liu, An-Jun; Chen, Ye-Fu.
Affiliation
  • Ji HY; College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China.
  • Liu C; College of Food Science and Engineering, Tianjin University of Science and Technology, Tianjin 300457, China.
  • Dai KY; College of Food Science and Engineering, Tianjin University of Science and Technology, Tianjin 300457, China.
  • Yu J; College of Food Science and Engineering, Tianjin University of Science and Technology, Tianjin 300457, China.
  • Liu AJ; College of Food Science and Engineering, Tianjin University of Science and Technology, Tianjin 300457, China. Electronic address: laj1456@163.com.
  • Chen YF; College of Biotechnology, Tianjin University of Science and Technology, Tianjin 300457, China. Electronic address: yfchen@tust.edu.cn.
Int Immunopharmacol ; 99: 108008, 2021 Oct.
Article de En | MEDLINE | ID: mdl-34330058
ABSTRACT
In the present study, the low molecular weight of chitosan (CS) was prepared and its activity on thymopentin-activated mice bearing H22 solid tumors was further researched. The purity and molecular weight of CS were determined by UV and HPGPC spectra, and its immunosuppressive effects on H22 tumor-bearing mice were evaluated through determination on immune organs, cells and cytokines. Results showed that CS contained little impurities with the average molecular weight of 1.20 × 104 Da. The in vivo antitumor experiments demonstrated that CS facilitated to destroy immune organs (thymuses and spleens), suppress immune cells (lymphocytes, macrophages and NK cells) activities and reduce immune-related cytokines (TNF-α, IFN-γ, IL-2 and IL-4) expressions of H22 tumor-bearing mice even with simultaneous TP5 stimulation. Our data suggested that CS could not be applied to improve immune response in cancer-bearing patients, but might be employed for treatments on autoimmune diseases or organ transplant patients.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Chitosane / Tumeurs du foie Limites: Animals Langue: En Journal: Int Immunopharmacol Sujet du journal: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Carcinome hépatocellulaire / Chitosane / Tumeurs du foie Limites: Animals Langue: En Journal: Int Immunopharmacol Sujet du journal: ALERGIA E IMUNOLOGIA / FARMACOLOGIA Année: 2021 Type de document: Article Pays d'affiliation: Chine